These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 26172925

  • 1. Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders.
    Polyzos NP, Corona R, Van De Vijver A, Blockeel C, Drakopoulos P, Vloeberghs V, De Vos M, Camus M, Humaidan P, Tournaye H.
    Gynecol Endocrinol; 2015; 31(11):885-90. PubMed ID: 26172925
    [Abstract] [Full Text] [Related]

  • 2. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, Tournaye H.
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [Abstract] [Full Text] [Related]

  • 3. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P, Vuong TNL, Ho NAV, Vaiarelli A, Ho MT, Blockeel C, Camus M, Lam AT, van de Vijver A, Humaidan P, Tournaye H, Polyzos NP.
    Hum Reprod; 2017 Nov 01; 32(11):2225-2233. PubMed ID: 29040589
    [Abstract] [Full Text] [Related]

  • 4. Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?
    Errázuriz J, Drakopoulos P, Pening D, Racca A, Romito A, De Munck N, Tournaye H, De Vos M, Blockeel C.
    Reprod Biomed Online; 2019 Jun 01; 38(6):1010-1017. PubMed ID: 30879911
    [Abstract] [Full Text] [Related]

  • 5. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP, Devos M, Humaidan P, Stoop D, Ortega-Hrepich C, Devroey P, Tournaye H.
    Fertil Steril; 2013 Feb 01; 99(2):422-6. PubMed ID: 23084565
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R, Nahum R, Zohav E, Liberty G, Anteby EY, Meltcer S.
    Gynecol Endocrinol; 2013 Jan 01; 29(1):51-3. PubMed ID: 22857268
    [Abstract] [Full Text] [Related]

  • 10. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG, Carvalho BR, Nakagawa HM, Rassi TRE, Barbosa ACP, Silva AA.
    JBRA Assist Reprod; 2017 Jun 01; 21(2):67-69. PubMed ID: 28609269
    [Abstract] [Full Text] [Related]

  • 11. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J, Sha A, Han D, Li P, Geng J, Ma C.
    Fertil Steril; 2014 Jul 01; 102(1):75-81. PubMed ID: 24746740
    [Abstract] [Full Text] [Related]

  • 12. GnRHa flare and IVF pregnancy rates.
    Confino E, Zhang X, Kazer RR.
    Int J Gynaecol Obstet; 2004 Apr 01; 85(1):36-9. PubMed ID: 15050465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
    Orvieto R, Volodarsky M, Hod E, Homburg R, Rabinson J, Zohav E, Anteby EY, Meltcer S.
    Gynecol Endocrinol; 2007 Apr 01; 23(8):494-6. PubMed ID: 17852411
    [Abstract] [Full Text] [Related]

  • 16. Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve.
    Yu R, Jin H, Huang X, Lin J, Wang P.
    J Int Med Res; 2018 Jun 01; 46(6):2327-2337. PubMed ID: 29695208
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.
    Tsakiridis I, Najdecki R, Tatsi P, Timotheou E, Kalinderi K, Michos G, Virgiliou A, Yarali H, Athanasiadis A, Papanikolaou EG.
    JBRA Assist Reprod; 2020 Oct 06; 24(4):436-441. PubMed ID: 32489086
    [Abstract] [Full Text] [Related]

  • 18. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG, Sfontouris IA, Venetis CA, Lainas GT, Zorzovilis IZ, Tarlatzis BC, Kolibianakis EM.
    Hum Reprod; 2015 Oct 06; 30(10):2321-30. PubMed ID: 26307091
    [Abstract] [Full Text] [Related]

  • 19. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.
    Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B, Devroey P.
    Fertil Steril; 2010 Oct 06; 94(5):1922-4. PubMed ID: 20149360
    [Abstract] [Full Text] [Related]

  • 20. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I, Stein DE, Keltz MD.
    Fertil Steril; 2010 Feb 06; 93(2):360-3. PubMed ID: 19131055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.